Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 10, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-24
DOI
10.1038/s41419-019-1597-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets
- (2018) Qilai Cheng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat
- (2017) Kenneth Kin-Wah To et al. LUNG CANCER
- Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity
- (2017) Lihui Wang et al. Cell Death & Disease
- Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins
- (2017) Jin Wang et al. Artificial Cells Nanomedicine and Biotechnology
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
- (2016) Zhaolin Chen et al. CANCER LETTERS
- Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
- (2016) D.A. Fennell et al. CANCER TREATMENT REVIEWS
- Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo
- (2016) Lihui Wang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
- (2016) Azusa Tanimoto et al. CLINICAL CANCER RESEARCH
- Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity
- (2016) Raffaella Cincinelli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure–Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4′-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein
- (2016) Stefano Guglielmo et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
- (2016) ZHIHAO WANG et al. ONCOLOGY REPORTS
- Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
- (2016) L Wang et al. Cell Death & Disease
- The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer
- (2015) N C Hait et al. Oncogenesis
- Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
- (2014) Wan Feng et al. CANCER LETTERS
- Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
- (2014) Nikola A. Bowden CANCER LETTERS
- Belinostat: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Effects of ornithine decarboxylase antizyme 1 on the proliferation and differentiation of human oral cancer cells
- (2014) XING WANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Assay of OAZ1 mRNA Levels in Chronic Myeloid Leukemia Combined with Application of Leukemia PCR Array Identified Relevant Gene Changes Affected by Antizyme
- (2013) Bingping Wu et al. ACTA HAEMATOLOGICA
- P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration
- (2013) Tetsuo Yamagishi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Wnt Signaling Pathway in Non-Small Cell Lung Cancer
- (2013) D. J. Stewart JNCI-Journal of the National Cancer Institute
- Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
- (2013) Christopher J. Millard et al. MOLECULAR CELL
- Histone deacetylase complexes as caretakers of genome stability
- (2012) Robert S. Lahue et al. Epigenetics
- P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation
- (2012) Lenka Gibalová et al. TOXICOLOGY IN VITRO
- Polyamine sensing by nascent ornithine decarboxylase antizyme stimulates decoding of its mRNA
- (2011) Leo Kurian et al. NATURE
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started